Superworth

STERIS free cash flow STE

Cash from operations less capital spending, by quarter and over the last twelve months, from 2018.

Last 12 months, to Jun 30, 2026
$925.6M
Latest quarter, Q1 FY27
$279.6M
−14% on a year earlier
Fiscal year 2026
$972.4M
+25% on the year before

STERIS' free cash flow was $925.6M over the twelve months to Jun 30, 2026, up 2% on a year earlier.

In its latest quarter, Q1 FY27, it was $279.6M, down 14% on the same quarter a year before.

Over the five fiscal years to FY2026 it grew 17% a year on average.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2026$972.4M+25%
FY2025$778M+27%
FY2024$612.9M+55%
FY2023$395M−1%
FY2022$397.2M−12%
FY2021$450.4M+20%
FY2020$376M+8%
FY2019$349.8Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q1 FY27$279.6M−14%$925.6M
Q4 FY26$245.2M+29%$972.4M
Q3 FY26$199.5M−18%$917.1M
Q2 FY26$201.3M+35%$961.2M
Q1 FY26$326.4M+67%$908.7M
Q4 FY25$189.9M+16%$778M
Q3 FY25$243.6M+41%$751.4M
Q2 FY25$148.8M+137%$680.1M
Q1 FY25$195.7M−9%$594.1M
Q4 FY24$163.3M+13%$612.9M
Q3 FY24$172.3M+51%$594M
Q2 FY24$62.8M+198%$535.4M

Against its peers

Companies in Healthcare nearest STERIS' size, closest first, today.

CompanyFree cash flow yield
STESTERIS4.1%
INCYIncyte8.2%
THCTenet Healthcare14.0%
UTHRUnited Therapeutics4.3%
LHLabcorp4.3%
DGXQuest Diagnostics5.1%
ZBHZimmer Biomet8.1%
MEDPMedpace3.8%
WSTWest Pharmaceutical Services1.6%
RVTYRevvity3.2%
DXCMDexCom4.8%
Peer median4.6%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on STERIS

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.